Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03867487 · ClinicalTrials.gov registry record · Phase 2
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
A Phase 2 study, sponsored by Justin Ryder.
- Not yet
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT03867487 is a Phase 2 study that has not yet begun recruiting, run by Justin Ryder. The registered enrollment target is 40 participants.
The verdict
NCT03867487, a Phase 2 study, has not yet begun recruiting, sponsored by Justin Ryder.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
Interventions
- DRUG Empagliflozin 10 MG
- DRUG Placebo Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2027-05-01 |
| Est. Completion | 2028-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03867487
The ClinicalTrials.gov registry entry for NCT03867487 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Justin Ryder, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Empagliflozin 10 MG is the first listed.
NCT03867487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03867487 about?
NCT03867487 is a clinical study titled "SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease". This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
What is the current status of trial NCT03867487?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2027-05-01. Estimated completion is 2028-02-01.
What interventions are being tested in trial NCT03867487?
The interventions under investigation include: Empagliflozin 10 MG (DRUG), Placebo Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03867487?
This trial is sponsored by Justin Ryder, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.